Literature DB >> 29352267

Differential susceptibility of striatal, hippocampal and cortical neurons to Caspase-6.

Anastasia Noël1,2, Libin Zhou1,2,3, Bénédicte Foveau1,2, P Jesper Sjöström2,4, Andréa C LeBlanc5,6,7.   

Abstract

Active cysteinyl protease Caspase-6 is associated with early Alzheimer and Huntington diseases. Higher entorhinal cortex and hippocampal Caspase-6 levels correlate with lower cognitive performance in aged humans. Caspase-6 induces axonal degeneration in human primary neuron cultures and causes inflammation and neurodegeneration in mouse hippocampus, and age-dependent memory impairment. To assess whether Caspase-6 causes damage to another neuronal system, a transgenic knock-in mouse overexpressing a self-activated form of Caspase-6 five-fold in the striatum, the area affected in Huntington disease, and 2.5-fold in the hippocampus and cortex, was generated. Detection of Tubulin cleaved by Caspase-6 confirmed Caspase-6 activity. The Caspase-6 expressing mice and control littermates were subjected to behavioral tests to assess Huntington disease-relevant psychiatric, motor, and cognitive deficits. Depression was excluded with the forced swim and sucrose consumption tests. Motor deficits were absent in the nesting, clasping, rotarod, vertical pole, gait, and open field analyzes. However, Caspase-6 mice developed age-dependent episodic and spatial memory deficits identified by novel object recognition, Barnes maze and Morris water maze assays. Neuron numbers were maintained in the striatum, hippocampus, and cortex. Microglia and astrocytes were increased in the hippocampal stratum lacunosum molecular and in the cortex, but not in the striatum. Synaptic mRNA profiling identified two differentially expressed genes in transgenic hippocampus, but none in striatum. Caspase-6 impaired synaptic transmission and induced neurodegeneration in hippocampal CA1 neurons, but not in striatal medium spiny neurons. These data revealed that active Caspase-6 in the striatal medium spiny neurons failed to induce inflammation, neurodegeneration or behavioral abnormalities, whereas active Caspase-6 in the cortex and hippocampus impaired episodic and spatial memories, and induced inflammation, neuronal dysfunction, and neurodegeneration. The results indicate age and neuronal subtype-dependent Caspase-6 toxicity and highlight the importance of targeting the correct neuronal subtype to identify underlying molecular mechanisms of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29352267      PMCID: PMC6030053          DOI: 10.1038/s41418-017-0043-x

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  59 in total

1.  Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke.

Authors:  Nsikan Akpan; Esther Serrano-Saiz; Brad E Zacharia; Marc L Otten; Andrew F Ducruet; Scott J Snipas; Wen Liu; Jennifer Velloza; Greg Cohen; Sergeyi A Sosunov; William H Frey; Guy S Salvesen; E Sander Connolly; Carol M Troy
Journal:  J Neurosci       Date:  2011-06-15       Impact factor: 6.167

2.  Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice.

Authors:  Valeria Uribe; Bibiana K Y Wong; Rona K Graham; Corey L Cusack; Niels H Skotte; Mahmoud A Pouladi; Yuanyun Xie; Konstantin Feinberg; Yimiao Ou; Yingbin Ouyang; Yu Deng; Sonia Franciosi; Nagat Bissada; Amanda Spreeuw; Weining Zhang; Dagmar E Ehrnhoefer; Kuljeet Vaid; Freda D Miller; Mohanish Deshmukh; David Howland; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2012-01-18       Impact factor: 6.150

3.  Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease.

Authors:  J C Hedreen; C E Peyser; S E Folstein; C A Ross
Journal:  Neurosci Lett       Date:  1991-12-09       Impact factor: 3.046

Review 4.  Huntington disease: clinical, genetic, and social aspects.

Authors:  M A Nance
Journal:  J Geriatr Psychiatry Neurol       Date:  1998       Impact factor: 2.680

5.  Single App knock-in mouse models of Alzheimer's disease.

Authors:  Takashi Saito; Yukio Matsuba; Naomi Mihira; Jiro Takano; Per Nilsson; Shigeyoshi Itohara; Nobuhisa Iwata; Takaomi C Saido
Journal:  Nat Neurosci       Date:  2014-04-13       Impact factor: 24.884

6.  Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.

Authors:  Dagmar E Ehrnhoefer; Nicholas S Caron; Yu Deng; Xiaofan Qiu; Michelle Tsang; Michael R Hayden
Journal:  Exp Neurol       Date:  2016-06-11       Impact factor: 5.330

Review 7.  Ageing and neuronal vulnerability.

Authors:  Mark P Mattson; Tim Magnus
Journal:  Nat Rev Neurosci       Date:  2006-04       Impact factor: 34.870

8.  HDAC inhibition facilitates the switch between memory systems in young but not aged mice.

Authors:  Malorie Dagnas; Jean-Louis Guillou; Thomas Prévôt; Nicole Mons
Journal:  J Neurosci       Date:  2013-01-30       Impact factor: 6.167

9.  Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Christian Landles; Andreas Weiss; Sophie Franklin; David Howland; Gill Bates
Journal:  PLoS Curr       Date:  2012-07-16

10.  Targeting caspase-6 and caspase-8 to promote neuronal survival following ischemic stroke.

Authors:  A P Shabanzadeh; P M D'Onofrio; P P Monnier; P D Koeberle
Journal:  Cell Death Dis       Date:  2015-11-05       Impact factor: 8.469

View more
  8 in total

Review 1.  The Role of Neuronal NLRP1 Inflammasome in Alzheimer's Disease: Bringing Neurons into the Neuroinflammation Game.

Authors:  Jeremy Kean Yi Yap; Benjamin Simon Pickard; Elaine Wan Ling Chan; Sook Yee Gan
Journal:  Mol Neurobiol       Date:  2019-05-20       Impact factor: 5.590

2.  Therapeutic potential of Nlrp1 inflammasome, Caspase-1, or Caspase-6 against Alzheimer disease cognitive impairment.

Authors:  Joseph Flores; Anastasia Noël; Marie-Lyne Fillion; Andréa C LeBlanc
Journal:  Cell Death Differ       Date:  2021-10-08       Impact factor: 12.067

3.  Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson's Disease.

Authors:  Giulia Costa; Maria Jose Sisalli; Nicola Simola; Salvatore Della Notte; Maria Antonietta Casu; Marcello Serra; Annalisa Pinna; Antonio Feliciello; Lucio Annunziato; Antonella Scorziello; Micaela Morelli
Journal:  Front Aging Neurosci       Date:  2020-05-07       Impact factor: 5.750

4.  Methylene blue inhibits Caspase-6 activity, and reverses Caspase-6-induced cognitive impairment and neuroinflammation in aged mice.

Authors:  Libin Zhou; Joseph Flores; Anastasia Noël; Olivier Beauchet; P Jesper Sjöström; Andrea C LeBlanc
Journal:  Acta Neuropathol Commun       Date:  2019-12-16       Impact factor: 7.801

5.  Caspase-6-cleaved Tau fails to induce Tau hyperphosphorylation and aggregation, neurodegeneration, glial inflammation, and cognitive deficits.

Authors:  Anastasia Noël; Bénédicte Foveau; Andréa C LeBlanc
Journal:  Cell Death Dis       Date:  2021-03-01       Impact factor: 8.469

6.  Caspase-1 inhibition improves cognition without significantly altering amyloid and inflammation in aged Alzheimer disease mice.

Authors:  Joseph Flores; Marie-Lyne Fillion; Andréa C LeBlanc
Journal:  Cell Death Dis       Date:  2022-10-11       Impact factor: 9.685

7.  Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging.

Authors:  Joseph Flores; Anastasia Noël; Bénédicte Foveau; Olivier Beauchet; Andréa C LeBlanc
Journal:  Nat Commun       Date:  2020-09-11       Impact factor: 14.919

8.  Rare CASP6N73T variant associated with hippocampal volume exhibits decreased proteolytic activity, synaptic transmission defect, and neurodegeneration.

Authors:  Libin Zhou; Kwangsik Nho; Maria G Haddad; Nicole Cherepacha; Agne Tubeleviciute-Aydin; Andy P Tsai; Andrew J Saykin; P Jesper Sjöström; Andrea C LeBlanc
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.